# Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes

> **NCT00592969** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 164 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** metformin
- **DRUG:** biphasic insulin aspart

## Key facts

- **NCT ID:** NCT00592969
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-12-03
- **Primary completion:** 2004-11-02
- **Final completion:** 2004-11-02
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00592969

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00592969, "Efficacy and Safety of Metformin Plus Biphasic Insulin Aspart 30 in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00592969. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*